This Biotech Stock 135% Jump Trims $44M: What Now Today
A biotech stock that surged 135% in a year suddenly sees a big investor trim its stake by about $44 million. Here’s h...
Glide path describes how a target date fund changes its asset mix as the target year approaches, balancing risk and growth for your retirement.
25,488 articlesA biotech stock that surged 135% in a year suddenly sees a big investor trim its stake by about $44 million. Here’s h...
As EV demand grows and policy shifts unfold, investors are sizing up 2026. This guide breaks down the chances of a re...
Amazon shares navigate a shifting tech landscape in 2026 as analysts map a path from near-term growth to a longer-ter...
A bold AI-based forecast from Meta envisions Bitcoin surging toward multi-year highs by year-end 2026, anchored by re...
A steep 2026 selloff has investors weighing Microsoft through a new lens. This guide breaks down the case for microso...
Tesla's latest moves in robotaxi expansion and a tease of a big announcement sparked a rally. Learn what drove the ju...
AI is reshaping markets faster than many investors expect. This no-brainer artificial intelligence (AI) stock story b...
Ethereum tests a critical barrier near $1,800 as traders watch for a breakout that could unlock a rally toward $2,000...
Predicting a full decade ahead is challenging, but a thoughtful framework can illuminate likely paths for where will ...
SpaceX's IPO headlines would be enormous and tempting. This article shares the one clear message I’d tell every inves...
Warby Parker lit up the market with a notable stock move this week. This article breaks down the drivers behind the s...
Remitly Global surged in early 2026 as it grabbed remittance market share and turned the corner on profitability. Thi...